Detail of "4828-27-7"

Reference

Active-substance release from suspension ointments

Active-substance release from suspension ointments. Franke-Augst, H.; Speiser, P.; Lutz, O. (Pharm. Inst., ETH, Zurich, Switz.). Pharm. Ind., 39(1), 76-82 (German) 1977. CODEN: PHINAN. DOCUMENT TYPE: Journal CA Section: 63 (Pharmaceuticals) An org. solvent-resistant diffusion app. is described for measuring the in vitro release of H2O-insol. microcryst. corticosteroid suspensions (0.1%) from ointment bases into nonaq. media. The theor. model of T. Higuchi (1961) is applicable to drug release from these ointments. The amt. of drug released is proportional to the square root of the time of release. The rate of release depends strongly on the chem. and physiochem. 4828-27-7 is just another one chemical used in this study. properties of the ointment base. The polarity of the release medium affects water-in-oil systems more than oil-in-water systems. .

Tricyclic antidepressant and corticosteroid combinations for the treatment of inflammatory disorders

Tricyclic antidepressant and corticosteroid combinations for the treatment of inflammatory disorders. Sackeyfio, Robyn; Fong, Jason; Hurst, Nicole; Manivasakam, Palaniyandi; Jost-Price, Edward Roydon; Zimmerman, Grant; Keith, Curtis; Borisy, Alexis (Combinatorx, Incorporated, USA). PCT Int. Appl. WO 2003006026 A1 23 Jan 2003, 26 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR.Some commonly used reagents like 338-95-4 and 4828-27-7 are used in this experiment. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: A61K031-56. APPLICATION: WO 2002-US20142 26 Jun 2002. PRIORITY: US 2001-PV304089 9 Jul 2001. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) Section cross-reference(s): 63 The invention features a method for treating a patient having an inflammatory disorder, by administering to the patient (i) a tricyclic antidepressant (e.g., amoxapine); and (ii) a corticosteroid (e.g., prednisolone) simultaneously or within 14 days of each other in amts. sufficient to reduce or inhibit inflammation. Amoxapine and prednisolone combinations were prepd. and assay for TNFa suppressing activity. .